[
    {
        "title": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.",
        "paper_uid": "2a7a858b",
        "reference": "Emery P. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases. 2015;74(1):19.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "paper_uid": "1fbf0f4e",
        "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "save_folder_path": null,
        "study_design": "SYSTEMATIC_REVIEW"
    }
]